RedHill Biopharma (RDHL) Change in Account Payables (2016 - 2022)

RedHill Biopharma (RDHL) has 7 years of Change in Account Payables data on file, last reported at -$554000.0 in Q4 2022.

• On a quarterly basis, Change in Account Payables rose 84.53% year-over-year to -$554000.0 in Q4 2022; TTM through Dec 2022 was -$7.4 million, a 6797.3% decrease from a year earlier, with the FY2025 full-year figure at -$437000.0, up 79.29% from the prior year.
• Change in Account Payables for Q4 2022 stood at -$554000.0, down from $411000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for RDHL reached as high as $6.8 million in Q2 2021 and fell as low as -$6.0 million in Q1 2022.
• Historically, Change in Account Payables has averaged -$28750.0 across 5 years, with a median of -$52500.0 in 2018.
• Across the five-year window, Change in Account Payables slumped 5235.9% in 2018 and jumped 2372.55% in 2020, its largest moves.
• Year by year, Change in Account Payables stood at -$543000.0 in 2018, then dropped by 12.34% to -$610000.0 in 2019, then surged by 917.05% to $5.0 million in 2020, then plunged by 171.85% to -$3.6 million in 2021, then soared by 84.53% to -$554000.0 in 2022.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$554000.0 in Q4 2022, $411000.0 in Q3 2022, and -$1.3 million in Q2 2022.